Boosting often overlooked long wavelength emissions of rare-earth nanoparticles for NIR-II fluorescence imaging of orthotopic glioblastoma

Liu, Zheng; Ren, Feng; Zhang, Hao; Yuan, Qiang; Jiang, Zhilin; Liu, Hanghang; Sun, Qiao; Li, Zhen

doi:10.1016/j.biomaterials.2019.119364

Cited by 85 publications

(64 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the quenching effect of hydroxyl groups on the DC emission (∼1500 nm) and the nar-row (∼10 nm) and weak absorption (cross-section of 10 -20 cm -2 ) of Er 3+ ions [20,27], amphiphilic polymers such as DSPE-PEG were usually used to wrap dyes (e.g. IR-808, IR-806) as organic sensitizer, which improved the solubility of nanoparticles and the NIR II fluorescence [34][35][36]. However, the wrapped dyes could be leaked and instable, which directly influenced the sensitizing efficiency in vitro and in vivo.…”

Section: Surface Modification Of Er-dcnps For Further Enhancement Of Their Nir Iib Fluorescence and Biocompatibilitymentioning

confidence: 99%

Engineering NIR-IIb fluorescence of Er-based lanthanide nanoparticles for through-skull targeted imaging and imaging-guided surgery of orthotopic glioma

et al. 2020

Self Cite

View full text Add to dashboard Cite

Highly sensitive and specific discrimination of brain tumor margins from the surrounding parenchyma remains a formidable challenge. Limited by the short of photostable probes with deep tissue penetration and high efficiency of crossing the blood-brain-barrier (BBB), the development of fluorescence-guided surgery (FGS) of brain tumors was markedly constrained. Herein, we report the capability of the strong second near-infrared-IIb (NIR IIb, 1500−1700 nm) fluorescence from Er-based lanthanide nanoparticles in imaging-guided surgery of orthotopic glioma. We designed an energy-cascaded Er 3+ -Ce 3+ -A 3+ (A = Yb, Ho, Tm) system and prepared a series of NaErF 4 :Ce@NaAF 4 @NaLuF 4 down-conversion nanoparticles (DCNPs) for optimizing the influence of NaAF 4 interlayer and Ce 3+ dopants. We modified the optimal NaErF 4 :2.5 %Ce@NaYbF 4 (0.9 nm)@NaLuF 4 DCNPs with Dye-brush polymer (Dye-BP) to facilitate 4 I 13/2 → 4 I 15/2 transition, which leads to an impressive 675-fold enhancement of 1525 nm fluorescence in aqueous solution under 808 nm excitation due to the excellent energy-cascaded downconversion (ECD), in comparison with that of NaErF 4 nanoparticles. We further modified these highly bright nanoparticles with tumor-targeting angiopep-2 peptide, and efficiently delivered them to the glioma by using the focused ultrasound sonication (FUS) to temporarily open the BBB. We obtained the highest tumorto-background ratio (TBR = 12.5) ever reported in the targeted NIR IIb fluorescence imaging of small orthotopic glioma (size < 3 mm, depth> 3 mm) through intact skull and scalp, which was drastically improved to ∼150 after cardiac perfusion and craniotomy to ensure the precise resection of tumor. More importantly, the size of glioma measured from the width of fluorescence profile is very close to that from T 2 -weighted MRI images. Our work provides the insights into engineering NIR IIb fluorescence of lanthanide nanoparticles, and demonstrates the great potential of NIR IIb fluorescence imaging-guided surgery of tumor.

show abstract

Section: Surface Modification Of Er-dcnps For Further Enhancement Of Their Nir Iib Fluorescence and Biocompatibilitymentioning

confidence: 99%

Engineering NIR-IIb fluorescence of Er-based lanthanide nanoparticles for through-skull targeted imaging and imaging-guided surgery of orthotopic glioma

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…d (i) Schematic illustration of the synthesis of water-soluble dye-sensitized core–shell NaNdF 4 @NaLuF 4 /IR-808@DSPE-PEG5000 NPs and their energy transfer mechanism. (ii) Application of the core–shell NaNdF 4 @NaLuF 4 /IR-808@DSPE-PEG5000 NPs in NIR-II fluorescence imaging of orthotopic glioblastoma under the ultrasound-mediated opening of the BBB, and rare-earth staining of brain tissue after delivery into the brain (Reprint with permission [ 126 ]. Copyright 2019, Elsevier) …”

Section: Fluorescence Imagingmentioning

confidence: 99%

“…Apart from chalcogenide core/shell QDs and carbon QDs, there are also other kinds of inorganic fluorescent nanoprobes for glioma imaging [ 125 , 126 ]. For example, Au nanoclusters (NCs) stabilized with zwitterionic molecules, were reported to conduct FL imaging of glioma [ 125 ].…”

Section: Fluorescence Imagingmentioning

confidence: 99%

Construction of nanomaterials as contrast agents or probes for glioma imaging

Zhao

Peng

et al. 2021

J Nanobiotechnol

View full text Add to dashboard Cite

Malignant glioma remains incurable largely due to the aggressive and infiltrative nature, as well as the existence of blood–brain-barrier (BBB). Precise diagnosis of glioma, which aims to accurately delineate the tumor boundary for guiding surgical resection and provide reliable feedback of the therapeutic outcomes, is the critical step for successful treatment. Numerous imaging modalities have been developed for the efficient diagnosis of tumors from structural or functional aspects. However, the presence of BBB largely hampers the entrance of contrast agents (Cas) or probes into the brain, rendering the imaging performance highly compromised. The development of nanomaterials provides promising strategies for constructing nano-sized Cas or probes for accurate imaging of glioma owing to the BBB crossing ability and other unique advantages of nanomaterials, such as high loading capacity and stimuli-responsive properties. In this review, the recent progress of nanomaterials applied in single modal imaging modality and multimodal imaging for a comprehensive diagnosis is thoroughly summarized. Finally, the prospects and challenges are offered with the hope for its better development.

show abstract

“…84 In particular, Cu-Se ultrasmall nanoparticles and rare earth nanoparticles, labelled with near-infrared (NIR) dyes, have been employed, at preclinical level, to monitor FUS-induced temporary opening of the BBB and following recovery, 85 as well as to detect glioma in orthotopic animal models. 86 In further studies, the aforementioned Cu-Se ultrasmall nanoparticles, loaded with doxorubicin (DOX) and labelled with NIR dyes, were used concurrently with FUS and photodynamic therapy, and demonstrated good efficacy against orthotopic tumour models. 87 Anyway, the nanocarriers discussed here below include only those used to overcome the BBB/BBTB without disruption, aiming to deliver anti-cancer drugs to the brain tumours.…”

Section: Preclinical Nanomedicinesmentioning

confidence: 99%

<p>Overcoming the Blood–Brain Barrier: Successes and Challenges in Developing Nanoparticle-Mediated Drug Delivery Systems for the Treatment of Brain Tumours</p>

Ferraris¹,

Cavalli²,

Panciani³

et al. 2020

IJN

View full text Add to dashboard Cite

High-grade gliomas are still characterized by a poor prognosis, despite recent advances in surgical treatment. Chemotherapy is currently practiced after surgery, but its efficacy is limited by aspecific toxicity on healthy cells, tumour cell chemoresistance, poor selectivity, and especially by the blood-brain barrier (BBB). Thus, despite the large number of potential drug candidates, the choice of effective chemotherapeutics is still limited to few compounds. Malignant gliomas are characterized by high infiltration and neovascularization, and leaky BBB (the so-called blood-brain tumour barrier); surgical resection is often incomplete, leaving residual cells that are able to migrate and proliferate. Nanocarriers can favour delivery of chemotherapeutics to brain tumours owing to different strategies, including chemical stabilization of the drug in the bloodstream; passive targeting (because of the leaky vascularization at the tumour site); inhibition of drug efflux mechanisms in endothelial and cancer cells; and active targeting by exploiting carriers and receptors overexpressed at the blood-brain tumour barrier. Within this concern, a suitable nanomedicine-based therapy for gliomas should not be limited to cytotoxic agents, but also target the most important pathogenetic mechanisms, including cell differentiation pathways and angiogenesis. Moreover, the combinatorial approach of cell therapy plus nanomedicine strategies can open new therapeutical opportunities. The major part of attempted preclinical approaches on animal models involves active targeting with protein ligands, but, despite encouraging results, a few number of nanomedicines reached clinical trials, and most of them include drug-loaded nanocarriers free of targeting ligands, also because of safety and scalability concerns.

show abstract

Boosting often overlooked long wavelength emissions of rare-earth nanoparticles for NIR-II fluorescence imaging of orthotopic glioblastoma

Cited by 85 publications

References 66 publications

Engineering NIR-IIb fluorescence of Er-based lanthanide nanoparticles for through-skull targeted imaging and imaging-guided surgery of orthotopic glioma

Engineering NIR-IIb fluorescence of Er-based lanthanide nanoparticles for through-skull targeted imaging and imaging-guided surgery of orthotopic glioma

Construction of nanomaterials as contrast agents or probes for glioma imaging

<p>Overcoming the Blood–Brain Barrier: Successes and Challenges in Developing Nanoparticle-Mediated Drug Delivery Systems for the Treatment of Brain Tumours</p>

Contact Info

Product

Resources

About